Clinical trial miss may deal blow to Targacept - Winston-Salem Journal: Business News

Monday, April 20th, 2015

Clinical trial miss may deal blow to Targacept

Print
Font Size:
Default font size
Larger font size

Posted: Monday, December 16, 2013 9:15 pm

A second clinical trial miss for Targacept Inc. – this time a drug compound targeting schizophrenia – may have dealt a crucial blow to the Winston-Salem company’s research and financial future.

Targacept develops drugs based on the use of nicotinic receptors to treat diseases, with a primary focus on the central nervous system. It has served as an anchor of the Triad's biotechnology sector for several years.

Subscription Required

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Choose an online service.

The following services are print only and offer no digital access

You must login to view the full content on this page.

Thank you for reading 20 free articles on our site. You can come back at the end of your 30-day period for another 20 free articles, or you can purchase a subscription and continue to enjoy valuable local news and information. If you need help, please contact our office at 336-727-7211. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Choose an online service.

The following services are print only and offer no digital access

 

loading...
  • BISHOP MCGUINESS

    • icon Updated: 10:01 pm
  • MITCHELL'S NURSERY

    • icon Updated: 10:01 pm